← All trials
NCT06328738
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 30, 2024
- Primary completion
- Jan 31, 2027
- Completion date
- Jul 31, 2028
- First posted
- Mar 25, 2024
- Last posted
- Nov 8, 2024
- Enrollment
- 255
- Arms / groups
- 13 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Enliven TherapeuticsLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.